Theriva Biologics Inc.

Company Profile

Theriva Biologics Inc. had its IPO on 2006-12-18 under the ticker symbol TOVX.

The company operates in the Healthcare sector and Biotechnology industry. Theriva Biologics Inc. has a staff strength of 21 employees.

Stock update

Shares of Theriva Biologics Inc. opened at $0.53 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.5 - $0.53, and closed at $0.51.

This is a +2% increase from the previous day's closing price.

A total volume of 26,768 shares were traded at the close of the day’s session.

In the last one week, shares of Theriva Biologics Inc. have increased by 0%.

Theriva Biologics Inc.'s Key Ratios

Theriva Biologics Inc. has a market cap of $8.78 million, indicating a price to book ratio of 0.163 and a price to sales ratio of 0.

In the last 12-months Theriva Biologics Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-23188000. The EBITDA ratio measures Theriva Biologics Inc.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Theriva Biologics Inc.’s operating margin was 0% while its return on assets stood at -19.71% with a return of equity of -37.46%.

In Q2, Theriva Biologics Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Theriva Biologics Inc.’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.39 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Theriva Biologics Inc.’s profitability.

Theriva Biologics Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.9066. Its price to sales ratio in the trailing 12-months stood at 0.

Theriva Biologics Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$65.45 million

Total Liabilities

$9.13 million

Operating Cash Flow

$0

Capital Expenditure

$9000

Dividend Payout Ratio

0%

Theriva Biologics Inc. ended 2024 with $65.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $65.45 million while shareholder equity stood at $47.75 million.

Theriva Biologics Inc. ended 2024 with $0 in deferred long-term liabilities, $9.13 million in other current liabilities, 18000.00 in common stock, $-300531000.00 in retained earnings and $5.62 million in goodwill. Its cash balance stood at $34.25 million and cash and short-term investments were $34.25 million. The company’s total short-term debt was $519,000 while long-term debt stood at $153000.00.

Theriva Biologics Inc.’s total current assets stands at $37.97 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $290000.00 compared to accounts payable of $741000.00 and inventory worth $-290000.00.

In 2024, Theriva Biologics Inc.'s operating cash flow was $0 while its capital expenditure stood at $9000.

Comparatively, Theriva Biologics Inc. paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.51

52-Week High

$1.4499

52-Week Low

$0.3899

Analyst Target Price

$4.5

Theriva Biologics Inc. stock is currently trading at $0.51 per share. It touched a 52-week high of $1.4499 and a 52-week low of $1.4499. Analysts tracking the stock have a 12-month average target price of $4.5.

Its 50-day moving average was $0.63 and 200-day moving average was $0.71 The short ratio stood at 4.18 indicating a short percent outstanding of 0%.

Around 90.6% of the company’s stock are held by insiders while 704.1% are held by institutions.